← all cases

Compare LLY and MRK on R&D-to-revenue ratio.

partial
clarity
4/5
comparison
4/5
evidence
3/5
honesty
4/5
faithfulness
5.0/5
elapsed
59.9s

Report

Profitability

Both LLY and MRK converged to nearly identical revenue levels by FY2025, but their trajectories and profitability dynamics differ sharply. LLY's revenues surged from $28.5B in FY2022 [LLY:Q0] to $65.2B in FY2025 [LLY:Q3]—a roughly 128% increase driven largely by GLP-1 and oncology franchises—while MRK's revenues grew more modestly from $59.3B [MRK:Q0] to $65.0B [MRK:Q3] over the same period. On the bottom line, LLY's net income rose from $6.2B in FY2022 [LLY:Q4] to $20.6B in FY2025 [LLY:Q7], though this was not a smooth ascent: net income dipped to $5.2B in FY2023 [LLY:Q5] before accelerating sharply, implying a net margin of roughly 32% in FY2025. MRK's net income trajectory was more volatile: a strong $14.5B in FY2022 [MRK:Q4] fell sharply to just $365M in FY2023 [MRK:Q5]—likely reflecting significant non-recurring charges associated with M&A activity, though the precise quantum of any IPR&D write-offs is not fully detailed in available filings—before recovering to $17.1B in FY2024 [MRK:Q6] and $18.3B in FY2025 [MRK:Q7], a net margin of approximately 28%. LLY's margin expansion is notable given its much faster revenue ramp, whereas MRK's profitability, while solid in absolute terms, reflects a larger and more mature base with less dramatic top-line growth.

LLY: Eli Lilly has delivered strong profitability improvement, with revenues nearly doubling from $34.1B in FY2023 [LLY:Q1] to $65.2B in FY2025 [LLY:Q3]. Net income followed a non-linear path—dipping to $5.2B in FY2023 [LLY:Q5] before rebounding to $20.6B in FY2025 [LLY:Q7]—but the ultimate trajectory underscores meaningful operating leverage embedded in its high-growth product portfolio, with a net margin of roughly 32% in FY2025.

MRK: Merck's profitability is solid but uneven: after earning $14.5B in net income in FY2022 [MRK:Q4], net income fell sharply to $365M in FY2023 [MRK:Q5], likely due to significant non-recurring charges tied to M&A activity, before rebounding strongly to $17.1B in FY2024 [MRK:Q6] and $18.3B in FY2025 [MRK:Q7]. Revenue growth has been steady but modest, rising from $59.3B [MRK:Q0] to $65.0B [MRK:Q3] over four years, reflecting a mature large-cap profile with a net margin of approximately 28% in FY2025.

R&D-to-Revenue Ratio

Insufficient data

Cross-Axis Takeaway

Critic flags (3)

weakly_supportedprofitability
LLY's net income expanded dramatically from $6.2B in FY2022 to $20.6B in FY2025
The endpoints are correct, but the word 'dramatically' and the implied smooth expansion obscure that LLY net income actually fell to $5.24B in FY2023 before recovering. The intermediate data point contradicts the 'dramatic expansion' narrative without qualification.
weakly_supportedprofitability
MRK's FY2023 net income collapse to $365M was 'likely reflecting large acquired in-process R&D charges'
The direction is correct and consistent with known MRK M&A activity in 2023, but no specific IPR&D charge amount for FY2023 is cited in the analyst's sources. The retrieved filing evidence only references $792M in intangible impairments in 2023 (not the full IPR&D write-off quantum). The claim is plausible but not directly evidenced by the cited sources.
weakly_supportedprofitability
All MRK quantitative figures (revenues and net income for FY2022–FY2025) are presented without any MRK citations
The analyst's citation list exclusively references quant:LLY XBRL concepts. MRK revenue and net income figures ($59.3B, $65.0B, $14.5B, $365M, $17.1B, $18.3B) are all numerically accurate per XBRL data but are uncited in the analysis, creating a traceability gap.

Cross-axis notes

The analysis notes LLY's revenue surge was 'largely driven by GLP-1 and oncology franchises' — this qualitative driver claim is not grounded in any cited filing text; it is a well-known fact but should be supported by a filing citation for full rigor.
LLY's FY2023 net income ($5.24B) was actually lower than FY2022 ($6.24B), meaning LLY's bottom-line trajectory was also non-monotonic, similar to MRK's — the analysis implies LLY had a smooth upward trajectory which is misleading without acknowledging the FY2023 dip.
The claim that both companies 'converged to nearly identical revenue levels by FY2025' is well-supported ($65.18B vs $65.01B), but the framing that MRK is a 'larger and more mature base' is slightly inconsistent with the fact that by FY2025 both companies are at essentially the same revenue scale.

Citations (16)

quant LLY FY2022
us-gaap:Revenues = $28.54B
quant LLY FY2023
us-gaap:Revenues = $34.12B
quant LLY FY2024
us-gaap:Revenues = $45.04B
quant LLY FY2025
us-gaap:Revenues = $65.18B
quant LLY FY2022
us-gaap:NetIncomeLoss = $6.24B
quant LLY FY2023
us-gaap:NetIncomeLoss = $5.24B
quant LLY FY2024
us-gaap:NetIncomeLoss = $10.59B
quant LLY FY2025
us-gaap:NetIncomeLoss = $20.64B
quant MRK FY2022
us-gaap:Revenues = $59.28B
quant MRK FY2023
us-gaap:Revenues = $60.12B
quant MRK FY2024
us-gaap:Revenues = $64.17B
quant MRK FY2025
us-gaap:Revenues = $65.01B
quant MRK FY2022
us-gaap:NetIncomeLoss = $14.52B
quant MRK FY2023
us-gaap:NetIncomeLoss = $365.00M
quant MRK FY2024
us-gaap:NetIncomeLoss = $17.12B
quant MRK FY2025
us-gaap:NetIncomeLoss = $18.25B